The aim of the study were 1) to verify whether lamotrigine (LTG) influences serum plasma levels (assessed by HPLC) of carbamazepine (CBZ) and CBZ-epoxide (CBZ-E) in patients affected by pharmacoresistant partial epilepsy and 2) if adverse effects of some of these patients might be somewhat related to this mechanism. LTG did not induce significant differences in plasma concentrations of CBZ and CBZ-E, even when plasma samples were taken during the clinical appearance of adverse effects.
Ulivelli, M., Dreassi, E., Rocchi, R., Corti, P., Vatti, G., Carapelli, S., et al. (1996). Carbamazepine and carbamazepine-epoxide plasma levels during lamotrigine add-on [Livelli plasmatici di carbamazepina e carbamazepina epossido dopo add-on di lamotrigina]. BOLLETTINO-LEGA ITALIANA CONTRO L'EPILESSIA, 95-96, 163-165.
Carbamazepine and carbamazepine-epoxide plasma levels during lamotrigine add-on [Livelli plasmatici di carbamazepina e carbamazepina epossido dopo add-on di lamotrigina]
Ulivelli M.;Dreassi E.;Rocchi R.;Battistini N.
1996-01-01
Abstract
The aim of the study were 1) to verify whether lamotrigine (LTG) influences serum plasma levels (assessed by HPLC) of carbamazepine (CBZ) and CBZ-epoxide (CBZ-E) in patients affected by pharmacoresistant partial epilepsy and 2) if adverse effects of some of these patients might be somewhat related to this mechanism. LTG did not induce significant differences in plasma concentrations of CBZ and CBZ-E, even when plasma samples were taken during the clinical appearance of adverse effects.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/18617
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo